- 1 **1.Title:** Gasdermin D-Mediated Neutrophil Pyroptosis drives Inflammation in Psoriasis
- 2
- **3 2.Authors:** Jian Liu<sup>\*1</sup>, YuYing Jiang<sup>\*2</sup>, ZiYue Diao<sup>\*1</sup>, DanDan Chen<sup>1</sup>, RuiYuan Xia<sup>1</sup>,
- 4 BingWei Wang#<sup>3</sup>, Shuo Yang#<sup>2</sup>, ZhiQiang Yin#<sup>1</sup>.
- 5 \* Jian Liu, YuYing Jiang and ZiYue Diao contributed equally to this work.
- <sup>1</sup>Department of Dermatology, First Affiliated Hospital of Nanjing Medical University,
- 7 Nanjing, China.
- 8 <sup>2</sup>Department of Immunology, State Key Laboratory of Reproductive Medicine and Offspring
- 9 Health, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative
- 10 Innovation Center for Personalized Cancer Medicine, Gusu School, the Affiliated Wuxi
- 11 People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical
- 12 Center, Nanjing Medical University, Nanjing, China.
- <sup>3</sup>Department of Pharmacology, Nanjing University of Chinese Medicine, 138 Xianlin
- 14 Avenue, Nanjing, China.
- 15

### 16 **3.Corresponding authors:**

- 17 ZhiQiang Yin, Email: yinzhiqiang@njmu.edu.cn
- 18 Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, 300
- 19 Guangzhou Road, Nanjing, Jiangsu 210029, China
- 20 Shuo Yang, Email: shuoyang01@njmu.edu.cn
- 21 Department of Immunology, State Key Laboratory of Reproductive Medicine and Offspring
- 22 Health, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative
- 23 Innovation Center for Personalized Cancer Medicine, Gusu School, the Affiliated Wuxi
- 24 People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical
- 25 Center, Nanjing Medical University, Nanjing, China, 211166
- 26 BingWei Wang, Email: bingweiwang@njucm.edu.cn
- 27 Department of Pharmacology, Nanjing University of Chinese Medicine, 138 Xianlin Avenue,
- 28 Nanjing, China, 210023
- 29
- **4.Funding sources**: This work was supported by the National Natural Science Foundation of
  China (82073439 and 82373475).
- 32
- 33 **5.Conflicts of Interest**: None declared.
- 34
- 35 6.Manuscript word count: 2466; Abstract word count: 169; References: 46; Figures: 4;
  36
- 37 **7.Keywords:** psoriasis; neutrophil; pyroptosis; gasdermin D; treatment
- 38 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 39 **Declarations**

- Ethics approval and consent to participate: 40 All mice were kept in a barrier facility, and all animal experiments were conducted in 41 42 accordance with the procedure approved by the Ethical Review Committee for 43 Laboratory Animal Welfare of the Nanjing Medical University (IACUC-2203023). 44 Human skin tissue samples were obtained from the Department of Dermatology, 45 Jiangsu Provincial People's Hospital, which was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province 46 47 Hospital), Ethics Number: 2020-SRFA-101, and informed consent was obtained from all study participants. 48
- 49
- 50 Consent for publication:
- 51 All authors agreed with the submission of this manuscript to *eLife* and consent for
- 52 publication was obtained.
- 53
- 54 Availability of data and material:
- The data and materials are available from the corresponding authors upon reasonablerequest.
- 57
- 58 Competing interests: None declared.
- 59
- Funding: This work was supported by the National Natural Science Foundation ofChina (82073439 and 82373475).
- 62
- 63 Authors' contributions:
- 64 Jian Liu: Data curation, Investigation, Methodology and Writing original draft
- 65 YuYing Jiang and ZiYue Diao: Data curation, Investigation and Methodology
- 66 DanDan Chen and RuiYuan Xia: Methodology
- BingWei Wang, Shuo Yan and ZhiQiang Yin: Conceptualization, Project
  administration, Supervision and Writing review & editing
- 70 Acknowledgements: None.
- 71

69

- 72
- 73
- 74
- 75
- 76 77

- 79
- 80
- 81
- 82

#### 83 Abstract

Psoriasis is a multifactorial immune-mediated inflammatory disease. Its pathogenesis involves abnormal accumulation of neutrophils and T-cell related abnormalities. Pyroptosis is a type of regulated cell death associated with innate immunity, but its role in psoriasis is unclear. In this study, we found that gasdermin D (Gsdmd) is higher in human psoriatic skin than that in normal skin, and in imiquimod-induced psoriasis-like mouse skin, the expression of *Gsdmd* was most significantly altered in neutrophils and *Illb* was also mainly expressed in neutrophils. Immunohistochemical staining of serial sections of skin lesions from psoriasis patients and healthy control also showed that GSDMD expression is higher in psoriasis lesion, especially in neutrophils. Gsdmd deficiency mitigates psoriasis-like inflammation in mice. GSDMD in neutrophils contributes to psoriasis-like inflammation, while Gsdmd depletion in neutrophils attenuates the development of skin inflammation in psoriasis and reduces the release of the inflammatory cytokines. We found that neutrophil pyroptosis is involved in and contributes to psoriasis inflammation, which provides new insights into the treatment of psoriasis by targeting neutrophil pyroptosis.

114 Gasdermin D-Mediated Neutrophil Pyroptosis drives Inflammation in Psoriasis

115

### 116 **1. Introduction**

117 Psoriasis is an autoimmune disease that involves multiple systems and manifests 118 primarily as plaques and scaling. The incidence of psoriasis displays significant 119 variation across populations, with estimates ranging from 0.47% in China to 8.5% in Norway, and 3.0% among adults in the United States [1-3]. The etiology of psoriasis is 120 multi-factorial and involves a complex interplay of genetic, environmental, infectious 121 and lifestyle factors. Previous studies have suggested that the pathogenesis of 122 psoriasis is related to the involvement of various cells, including immune cells, 123 keratinocytes and stromal cells, and the underlying mechanism is complex[4]. The 124 125 participation of immune cells remains a research focus. Most biologics utilized to 126 treat psoriasis presently target the immune pathway. Current studies suggest that the interleukin 23 (IL-23)/T-helper 17 (Th17) immune axis is the primary immune 127 pathway involved in psoriasis pathogenesis[5]. Th17 cells play a significant role in 128 the pathogenesis of many autoimmune and inflammatory diseases. Th17-derived 129 proinflammatory cytokines, such as IL-17A, IL-17F, and IL-22 are critical in the 130 131 development of psoriasis[6]. Studies have shown that IL-17A contributes to both an adaptive immune circuit involving specific T-cell subsets and an innate axis between 132 133 keratinocytes and neutrophils[7]. Except for Th17 cells, Neutrophils within the skin are a hallmark feature of psoriasis. Neutrophils accumulate in the dermis and 134 135 epidermis, resulting in the formation of Kogoj pustules and Munro microabscesses [8]. Neutrophils are increased in the skin and blood of patients with psoriasis,[9] and 136 promote psoriasis by secreting proinflammatory mediators and proteases through 137 138 degranulation or forming neutrophil extracellular traps[10-12]. Nevertheless, the mechanisms by which neutrophils promote and exacerbate inflammation in psoriasis 139 140 remain under investigation.

Pyroptosis is a type of regulated cell death triggered by the inflammasome and 141 mediated by the gasdermin family[13]. Gasdermin D (GSDMD) is currently the most 142 extensively researched member of the gasdermin family. After perturbations of 143 144 extracellular or intracellular homeostasis related to innate immunity, the classical and non-classical pathways activate caspase 1 and caspase 4/5/11 (caspase 4/5 in humans 145 and caspase 11 in mice)[14], and the activated caspases cleave GSDMD into its 146 147 N-terminal and C-terminal fragments[15]. The N-terminus of GSDMD forms a 148 transmembrane pore, which releases inflammatory mediators [16, 17] and results in 149 proinflammatory cell death[18]. In recent years, there has been a focus on the role of 150 pyroptosis in infections, tumors, and autoimmune diseases[19-22] due to its potential 151 to cause inflammatory diseases when occurring excessively.

While previous studies have showed that the expression of GSDMD is increased in lesions of patients with psoriasis[23], and the pyroptosis of keratinocytes plays a role in inflammation seen in psoriasis[24]. However, the exact contribution of immune cell pyroptosis to the development of psoriasis remains unclear. Therefore, our study aimed to investigate the role of GSDMD-mediated immune cell pyroptosis in psoriasis.

158

## 159 **2. Methods**

160 2.1 Experimental animals

All mice were of the species Mus musculus (C57BL/6). All experiments were 161 performed with female mice (6–8 weeks old). The  $Gsdmd^{-1}$  mice were provided by Dr. 162 Feng Shao (National Institute of Biological Sciences, Beijing, China). The Gsdmd<sup>fl/fl</sup> 163 mice were generated using conditional gene targeting methods as described 164 previously[25]. All mice were kept in a barrier facility, and all animal experiments 165 were conducted in accordance with the procedure approved by the Ethical Review 166 Committee for Laboratory Animal Welfare of the Nanjing Medical University 167 (IACUC-2203023). 168

169 2.2 Psoriasis-like mouse model

Psoriasis-like mice were induced by 5% imiquimod (IMQ) cream as previously described [26]. Mice received a topical application of 32.5 mg 5% IMQ on the shaved dorsal skin for 4 days, and control mice were given the same dose of Vaseline for 4 days. The skin was examined every day, and the dorsa were photographed. The mice were sacrificed by cervical dislocation on day 5, and their skin and serum were collected for the next experiment.

176 2.3 Western blot

177 Mice back skin tissues were lysed in lysis buffer solution [150 mM NaCl, 10 mM tris (pH 7.4), 5 mM EDTA, 1 mM EGTA, and 0.1%NP-40] supplemented with 1 mM 178 179 phenylmethylsulphonyl fluoride, and complete protease inhibitor "cocktail" [Sigma-Aldrich]), followed by tissue homogenization and incubation for 60 min at 180 4°C. The lysates were centrifuged for 10 min at 14,000 g, and supernatants were 181 182 denatured with SDS buffer, and boiled for 10 min. Proteins were separated by SDSpolyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. 183 184 The membranes were immunoblotted with primary antibodies and proteins detected with appropriate secondary anti-rabbit antibody conjugated to fluorescence. 185 186 Immunoreactivity was visualized by the Odyssey Imaging System (LI-COR 187 **Biosciences**).

188 2.4 Enzyme-linked immunosorbent assay

Homogenized the mouse back skin tissues (the method is the same as before), and collected the supernatant. Supernatant were collected and measured for the level of IL-1 $\beta$  (DY401) and IL-6 (DY406) according to manufacturer's instructions by sandwich enzyme-linked immunosorbent assay (ELISA) (R&D System).

193 2.5 Immunofluorescence and Immunohistochemistry staining

194 For immunofluorescence, the mice skin tissues were collected, fixed in 4% buffered 195 formaldehyde, and embedded in paraffin. Tissue sections were incubated at 4°C overnight with primary antibody to GSDMD (Abcam, 1:300) and Ly6G (BDscience, 196 1:100). Slides were then incubated with indicated secondary antibodies. TUNEL 197 staining was carried out with staining kit (Servicebio). The nuclei were counterstained 198 199 with 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). Slides were dried and 200 mounted using ProLong Antifade mounting medium (Beyotime Biotechnology). Slides were visualized using a Nikon 50i fluorescence microscope. For 201

immunohistochemical staining, human skin tissue samples were obtained from the 202 Department of Dermatology, Jiangsu Provincial People's Hospital. Our study was 203 approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical 204 205 University (Jiangsu Province Hospital), Ethics Number: 2020-SRFA-101, and 206 informed consent was obtained from all study participants. Sections were blocked and 207 incubated with primary antibodies to GSDMD (Abcam, 1:1000) and CD66b (Biolegend, 1:80) after heat-induced antigen retrieval. Slides were then incubated with 208 209 horseradish peroxidase-conjugated secondary antibodies. Diaminobenzidine was used for detection. Images were captured with a Nikon 50i microscope. Images were 210 processed using ImageJ 1.53c and AdobePhotoshopCS6 software. 211

212 2.6 Flow cytometry (FCM) and Fluorescence Activated Cell Sorting (FACS)

213 For FCM, skin tissue was digested into single cell suspensions with collagenase P 214 (ROCHE, 1mg/mL), DNaseI (ROCHE, 100µg/ml), and HAase (ABSIN, 10µg/mL) at 37°C for 1 hour. Single cell suspensions were stained with anti-CD45-Alexa Flour 215 700 (eBioscience, 1:400), anti-Ly6G-eFlour 450 (eBioscience, 1:400), and FVD 216 217 eFlour 506 (eBioscience,1:1000) for Flow cytometry (Thermo). After the mice were 218 euthanized, the long bones were separated and the bone marrow was aspirated with a 219 sterile syringe. Single cell suspension was stained with anti-CD45-Alexa Flour 700 220 (eBioscience, anti-CD11b-Percp-cy5.5 1:400), (eBioscience, 1:400)and 221 anti-Ly6G-eFlour 450(eBioscience, 1:400) for FACS analysis (Thermo), CD45<sup>+</sup>FVD<sup>-</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup> neutrophils were obtained by FACS. All flow cytometry 222 223 analyses were performed on an Attune NxT Flow Cytometer (Thermo Fisher Scientific), and data were analyzed using FlowJo 10 software. 224

225 2.7 Neutrophil depletion

An injection of anti-Ly6G antibody (Selleck, 200µg) was given on day-1 and day2
during continuous IMQ application to deplete neutrophil in mice.

228 2.8 Statistical analysis

229 Data were analyzed using Prism 8 (GraphPad, San Diego, CA, USA). Comparisons 230 between two groups were analyzed by using unpaired Student's t-test. All data are 231 presented as the mean  $\pm$  SEM and are representative of at least three independent 232 experiments. P < 0.05 was considered indicative of statistical significance. \* p  $\leq$  0.05, 233 \*\* p < 0.01, \*\*\* p < 0.001, \*\*\*\* p  $\leq$  0.0001, ns p > 0.05.

234

## **3. Results**

236 3.1 The GSDMD-mediated pyroptosis is activated in psoriasis.

237 By searching the GEO database, we found that Gsdmd is higher in human 238 psoriatic skin than that in normal skin, and the similar trend was seen in IMO-induced psoriasis model mice compared to controls (Fig.1a). Immunohistochemical staining 239 of serial sections of skin lesions from psoriasis patients and healthy control also 240 241 showed that GSDMD expression is higher in psoriasis patients (Fig.1b). To further 242 elucidate the presence of pyroptosis in psoriasis, we induced a psoriasis-like mouse 243 model by applying IMQ (Fig.1c). The lesions of the mice were collected for western 244 blotting, our results indicated that the IMQ-treated group not only has elevated expression of caspase 1 and GSDMD relative to controls, but also shows functional 245

cleavage of 30KD GSDMD N fragment (Fig.1d-e). Hence, the activation of
 pyroptosis-associated molecules was found in psoriasis lesions.

248

249 3.2 GSDMD deficiency mitigates psoriasis-like inflammation in mice.

Given the particular elevation of GSDMD levels in psoriasis, we questioned 250 251 whether GSDMD contributed to psoriasis pathogenesis. We treated WT and GSDMD deficient mice with IMQ to induce psoriasis (Fig.1c). We found that the psoriasis area 252 and severity index (PASI)scores were significantly lower in Gsdmd<sup>-/-</sup> mice than WT 253 after 4 days of IMO application (Fig.2a-b). Moreover, indicators to assess the severity 254 255 of psoriasis, including acanthosis, parakeratosis, and microabscess formation as well as infiltration of leukocytes, were less pronounced in *Gsdmd<sup>-/-</sup>* mice compared with 256 WT (Fig.2c). We verified the absence of GSDMD in the skin of  $Gsdmd^{-/-}$  mice by 257 western blotting and found that after induction of psoriasis in  $Gsdmd^{-/-}$  mice, the 258 expression and activation of caspase 1, an upstream molecule of pyroptosis, were 259 decreased (Fig.2d). Levels of the pro-inflammatory cytokines in protein and mRNA 260 were also examined in the skin using ELISA and quantitative PCR, respectively. Our 261 262 results showed that the levels of inflammatory cytokines in psoriasis such as IL17a, 263 TNF- $\alpha$ , IL6, IL-1 $\beta$  and IL18 were substantially higher in the WT mice than in the  $Gsdmd^{-}$  mice (Fig.2e-f). These results demonstrated that the absence of GSDMD 264 265 ameliorated IMQ-induced psoriasiform dermatitis in mice.

266

267 3.3 Neutrophils undergo GSDMD mediated pyroptosis in psoriasis.

Previous studies have shown that pyroptosis occurs in psoriasis[24, 27]. 268 269 Moreover, neutrophils are critical to the pathogenesis of psoriasis, which is usually 270 characterized by a high accumulation of neutrophils both in lesions as well as in 271 blood[28]. Therefore, we wanted to clarify whether neutrophils undergo pyroptosis in 272 psoriasis. Firstly, we searched the GEO database and found that psoriasis patients' neutrophils showed higher expression of GSDMD (Fig.3a). Serial sections of skin 273 lesions from psoriasis patients were immunohistochemically stained with CD66b and 274 GSDMD antibodies. We further found that GSDMD was prominently expressed in 275 neutrophils, especially in Munro's microabscesses, which were indicated by CD66b in 276 the patients' skin of both psoriasis vulgaris and pustular psoriasis (Fig.3b). Through 277 database search and analysis, we found that in psoriasis-like mouse skin, the 278 expression of *Gsdmd* was most significantly altered in neutrophils (Fig.3c). Then, we 279 280 carried out immunofluorescent analysis of GSDMD in the psoriatic skin tissues of 281 WT mice and GSDMD-deficient mice used as a negative control. Lymphocyte antigen 282 6 (Ly6G), a classical neutrophil marker [29, 30], was found to be mainly expressed in neutrophils in the skin of IMQ-induced psoriasis-like mice (S1a). Therefore, we chose 283 Ly6G as a marker for mouse neutrophils in our experiments. In line with GEO data, 284 immunofluorescence staining showed that GSDMD was more strongly expressed in 285 the mice skin of IMQ applied group than control, including the significant localization 286 287 of GSDMD in neutrophils (Fig.3d). To further confirm that these neutrophils 288 underwent pyroptosis, we used flow cytometry to stain PI to confirm neutrophil pyroptosis and performed TUNEL staining on mouse skin after IMQ application to 289

exclude other cell deaths such as apoptosis (Fig.3e, S1b), these data suggest that
GSDMD-mediated pyroptosis exists in neutrophils infiltrating into psoriatic lesions as
shown more PI staining but not change in TUNEL staining in neutrophils.

293

3.4 GSDMD depletion in neutrophils attenuates the development of skininflammation in psoriasis.

To investigate the specific effect of neutrophils in psoriasis, we bred  $Gsdmd^{fl/fl}$ ; 296 *S100a8*<sup>cre/+</sup>(cKO) mice to make conditionally knockout GSDMD in neutrophils. There 297 are many previous studies using S100A8-Cre mice to knockout neutrophil-specific 298 299 genes[31, 32]. And we found that S100a8 is mainly expressed in neutrophils in psoriasis-like mouse skin (S1c). Therefore, we believe that the knockout effect of 300 301 GSDMD in cKO mice on other cells is quite small. We isolated bone marrow-derived 302 neutrophils and demonstrated by immunoblotting that GSDMD expression was reduced in cKO neutrophil (Fig.4a). Then we applied IMQ to the cKO and control 303 mice  $(Gsdmd^{fl/fl}; S100a8^{+/+})$  mice on a continuous basis for 4 days to induce psoriasis. 304 Our results showed that after induction of psoriasis, cKO mice had milder disease 305 306 than controls, as evidenced by reduced PASI scores and the apparent remission of skin 307 changes shown by HE staining, including acanthosis, parakeratosis, and infiltration of leukocytes (Fig.4b-d). And the lower levels of inflammatory cytokines, including 308 IL-17a, TNF- $\alpha$ , IL-6, IL-1 $\beta$  and IL-18, were also showed in cKO mice (Fig.4e-f). 309 310 Notably, although neutrophil-specific deletion of GSDMD mice showed a reduction 311 in psoriasis-like symptoms after induction, the reduction was not as pronounced as in GSDMD full knockout mice, suggesting that additional cellular pyroptosis may also 312 313 be involved in psoriasis pathogenesis. To further investigate neutrophilic pyroptosis in 314 psoriasis, we detected the expression of GSDMD and its N-terminal fragments by WB in the psoriatic skin of WT mice, Gsdmd<sup>-/-</sup> mice and cKO mice. We found that after 315 psoriasis induction, the GSDMD N-terminus was only weakly expressed in the skin of 316 cKO mice, whereas it was strongly expressed in WT mice (Fig4g), suggesting that 317 318 GSDMD-mediated neutrophil pyroptosis is one of the important components of cell pyroptosis in psoriasis. In addition, we used Ly6G antibody to eliminate neutrophils in 319 320 cKO mice and control mice. It was found that the difference in lesions between the 321 two groups was abolished after neutrophil depletion (Fig4i, S2a), indicating that 322 neutrophil pyroptosis plays an important role in the pathogenesis of imiquimod-induced psoriasis-like lesions in mice. 323

324 Considering that pyroptosis is a form of regulated cell death that results in 325 inflammation, its effects can be linked to the release of inflammatory cytokines 326 through membrane pores formed by GSDMD. While neutrophils do undergo 327 pyroptosis, they may exhibit resistance to this cytolytic effect, leading to sustained cytokine release. IL-1B, a significant inflammatory cytokine of pyroptosis, has a 328 329 crucial function in the pathogenesis of psoriasis. The IL-1β-IL-1R pathway promotes the ailment by regulating IL-17-producing cells in the dermis and stimulating 330 331 keratinocytes to magnify inflammatory cascades. Therefore, it is hypothesized that the 332 occurrence of neutrophil pyroptosis in psoriasis may activate inflammatory pathways downstream by releasing cytokine IL-1<sup>β</sup>. In order to further verify our hypothesis, we 333

analyzed publicly available single cell sequencing data. We found that in the skin of 334 psoriasis-like mice. *Illb* and *Il6* were mainly expressed in neutrophils, while *Ill7a* 335 was mainly expressed in T cells, 1118 was mainly expressed in macrophages and 336 fibroblasts, and *Tnfa* was mainly expressed in macrophages and T cells (S2b). This 337 suggests that neutrophil pyroptosis may affect the secretion of cytokines such as IL-1B 338 339 and IL-6 by neutrophils, thereby affecting the functions of other immune cells such as T cells and macrophages, forming a complex inflammatory network in psoriasis and 340 341 participating in the pathogenesis of psoriasis.

343 4 Discussion

342

In this study, we dissected the role of GSDMD protein, a key pyroptosis 344 345 executioner, in the context of psoriasis. We found that GSDMD protein was activated 346 in the skin of psoriasis, and that GSDMD in neutrophils promotes psoriasis inflammation through pyroptosis and the release of cytokines. Research on pyroptosis 347 has tended to focus on infections, tumors, and other acute inflammations. Pyroptosis 348 is not only involved in the regulation of sepsis, but also mediates sepsis-related organ 349 damage[33]. This means that while moderate pyroptosis promotes clearance of 350 351 pathogens, excessive pyroptosis can lead to uncontrolled inflammatory responses and promote the onset and development of sepsis[33-35]. Moreover, pyroptosis promotes 352 353 severe pancreatitis and associated lung injury through the release of cytokines IL-1 $\beta$ and IL-18[36], and is implicated in acute myocardial injury and spinal cord injury[37, 354 355 38]. In addition, GSDMD induced pyroptosis of antigen presenting cells in tumor microenvironments impairs antigen presentation in response to anti-PD-L1 356 357 treatment[22]. Only in recent years, studies have explored the function of pyroptosis 358 in psoriasis. Iwona Flisiak et al. found that GSDMD expression was significantly 359 increased in the skin of psoriasis patients, suggesting that it may be involved in the 360 pathogenesis of psoriasis[23]. Xu Chen et al. reported that GSDMD-mediated keratinocyte pyroptosis promotes excessive proliferation and abnormal differentiation 361 induced by the immune microenvironment in psoriatic skin inflammation, thus 362 contributing to the pathogenesis of psoriasis[24]. In addition, there are some studies 363 on pyroptosis-related proteins upstream of GSDMD, such as NLPR3 inflammasome 364 and AIM2 inflammasome, which are involved in and promote psoriasis through 365 downstream inflammatory cytokines[27, 39, 40]. 366

Consistent with earlier research, our study found that the expression of GSDMD 367 and its upstream molecule caspase 1 was upregulated in the skin of psoriasis patients 368 369 and psoriasis-like mice, indicating that the pyroptosis pathway is activated in psoriasis 370 skin lesions. Knockout of GSDMD in vivo is effective in significantly ameliorating 371 IMQ-induced psoriasis-like lesions and reducing the level of skin inflammation, 372 which also notably reduces the expression of the pyroptosis-inducing inflammatory 373 cytokine IL-1<sup>β</sup>. In our study, we found that the upregulated GSDMD signal was more significant in neutrophils in both human and animal tissues. In addition, specific 374 375 knockout of GSDMD in neutrophils in vivo can also yield results consistent with 376 GSDMD KO mice, although not as obvious as in KO mice. Our study is for the first time demonstrating that GSDMD-mediated neutrophil pyroptosis in psoriasis is 377

involved in psoriatic inflammation and may affect the inflammatory network in 378 psoriasis. Considering the role and early recruitment of neutrophils in psoriasis[28, 379 41], it is readily accepted that neutrophils act as innate immune cells in response to 380 changes in the microenvironment to initiate pyroptosis signaling and release cytokines 381 382 to engage and maintain psoriasis inflammation. IL-1 $\beta$  released by pyroptosis may 383 amplify the inflammatory cascade through the IL-1β-IL-1R pathway via direct regulation of dermal IL-17-producing cells and stimulation of keratinocytes[42], 384 thereby contributing to skin inflammation and psoriasis. In addition, the unique 385 resistance of neutrophils to pyroptosis[43] makes it reasonable for them to 386 continuously release cytokines after activation of the pyroptosis pathway and further 387 stimulate skin inflammation. 388

389 Nevertheless, combining previous studies and our findings, we can believe that 390 GSDMD-mediated pyroptosis, which is a dynamic biological process, particularly neutrophil pyroptosis, is involved in the inflammation of psoriasis, especially in the 391 early stage. This provides a potential basis for the possible use of drugs targeting 392 pyroptosis, especially drugs targeting neutrophil pyroptosis, in the treatment of 393 psoriasis. Dimethyl fumarate is a type of medicine widely used to treat psoriasis in 394 395 Europe[44, 45]. The latest research proves that dimethyl fumarate can inhibit the 396 function of GSDMD and thereby inhibit pyroptosis-related inflammation[46].

There is some limitation in our study such as the lack of exploration of upstream signaling involved in neutrophil pyroptosis along with its specific molecular mechanisms. Nevertheless, our study showed that neutrophil pyroptosis is involved in and contributes to psoriasis inflammation, indicating potential avenues and foundations for novel psoriasis treatment strategies.

#### 403 **References:**

- 404 1. Pezzolo, E. and L. Naldi, *Epidemiology of major chronic inflammatory immune-related*
- 405 *skin diseases in 2019.* Expert review of clinical immunology, 2020. **16**(2): p. 155-166.
- 406 2. Armstrong, A.W., et al., *Psoriasis prevalence in adults in the United States.* JAMA
- 407 dermatology, 2021. **157**(8): p. 940-946.
- 408 3. Ding, X., et al., *Prevalence of psoriasis in China: a population-based study in six cities.*
- 409 European Journal of Dermatology, 2012. **22**(5): p. 663-667.
- 410 4. Guo, J., et al., *Signaling pathways and targeted therapies for psoriasis.* Signal
- 411 Transduction and Targeted Therapy, 2023. **8**(1): p. 437.
- 412 5. Girolomoni, G., et al., The role of IL-23 and the IL-23/TH 17 immune axis in the

- 413 *pathogenesis and treatment of psoriasis.* Journal of the European Academy of
- 414 Dermatology and Venereology, 2017. **31**(10): p. 1616-1626.
- 415 6. Li, B., et al., *The role of Th17 cells in psoriasis.* Immunologic research, 2020. 68: p.
- 416 296-309.
- 417 7. Reich, K., et al., *Evidence that a neutrophil–keratinocyte crosstalk is an early target of*
- 418 *IL-17A inhibition in psoriasis.* Experimental dermatology, 2015. **24**(7): p. 529-535.
- 8. Schön, M.P., S.M. Broekaert, and L. Erpenbeck, *Sexy again: the renaissance of neutrophils in psoriasis.* Experimental dermatology, 2017. 26(4): p. 305-311.
- 421 9. Rodriguez-Rosales, Y.A., et al., *Immunomodulatory aged neutrophils are augmented*
- 422 *in blood and skin of psoriasis patients.* Journal of Allergy and Clinical Immunology,
- 423 2021. **148**(4): p. 1030-1040.
- 424 10. Wang, Z. and D. Shi, *Research progress on the neutrophil components and their*425 *interactions with immune cells in the development of psoriasis.* Skin Research and
- 426 Technology, 2023. **29**(7): p. e13404.
- 427 11. Chen, J., et al., *Neutrophils enhance cutaneous vascular dilation and permeability to*
- 428 *aggravate psoriasis by releasing matrix metallopeptidase 9.* Journal of Investigative
  429 Dermatology, 2021. **141**(4): p. 787-799.
- 430 12. Shao, S., et al., *Neutrophil extracellular traps promote inflammatory responses in*431 *psoriasis via activating epidermal TLR4/IL-36R crosstalk.* Frontiers in immunology,
- 432 2019. **10**: p. 746.
- 433 13. Galluzzi, L., et al., *Molecular mechanisms of cell death: recommendations of the*434 *Nomenclature Committee on Cell Death 2018.* Cell Death & Differentiation, 2018.

- 435 **25**(3): p. 486-541.
- 436 14. Kesavardhana, S., R.S. Malireddi, and T.-D. Kanneganti, *Caspases in cell death,*
- 437 *inflammation, and pyroptosis.* Annual review of immunology, 2020. **38**: p. 567-595.
- 438 15. Kovacs, S.B. and E.A. Miao, *Gasdermins: effectors of pyroptosis.* Trends in cell
- 439 biology, 2017. **27**(9): p. 673-684.
- 440 16. Evavold, C.L., et al., *The pore-forming protein gasdermin D regulates interleukin-1*
- 441 *secretion from living macrophages.* Immunity, 2018. **48**(1): p. 35-44. e6.
- 442 17. Heilig, R., et al., *The Gasdermin-D pore acts as a conduit for IL-1β secretion in mice.*
- 443 European journal of immunology, 2018. **48**(4): p. 584-592.
- 18. Banerjee, I., et al., *Gasdermin D restrains type I interferon response to cytosolic DNA*
- 445 *by disrupting ionic homeostasis.* Immunity, 2018. **49**(3): p. 413-426. e5.
- 446 19. You, R., et al., *Pyroptosis and its role in autoimmune disease: a potential therapeutic*
- 447 *target.* Frontiers in immunology, 2022. **13**: p. 841732.
- 448 20. Fang, Y., et al., *Pyroptosis: a new frontier in cancer.* Biomedicine & Pharmacotherapy,
- 449 2020. **121**: p. 109595.
- 450 21. Yu, P., et al., *Pyroptosis: mechanisms and diseases.* Signal transduction and targeted
  451 therapy, 2021. 6(1): p. 128.
- 452 22. Jiang, Y., et al., *Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint*453 *blockade.* Cell Reports, 2022. 41(4).
- 454 23. Nowowiejska, J., et al., Gasdermin D (GSDMD) Is Upregulated in Psoriatic Skin—A
- 455 New Potential Link in the Pathogenesis of Psoriasis. International Journal of Molecular

456 Sciences, 2023. **24**(17): p. 13047.

- 457 24. Lian, N., et al., *Gasdermin D-mediated keratinocyte pyroptosis as a key step in*458 *psoriasis pathogenesis.* Cell Death & Disease, 2023. **14**(9): p. 595.
- 459 25. Li, S., et al., Gasdermin D in peripheral myeloid cells drives neuroinflammation in
- 460 *experimental autoimmune encephalomyelitis.* Journal of Experimental Medicine, 2019.
- 461 **216**(11): p. 2562-2581.
- 462 26. Kim, S.H., et al., Pellino-1 promotes intrinsic activation of skin-resident IL-17A-
- 463 producing T cells in psoriasis. Journal of Allergy and Clinical Immunology, 2023.
- 464 **151**(5): p. 1317-1328.
- 465 27. Deng, G., et al., Inhibition of NLRP3 inflammasome-mediated pyroptosis in
- 466 macrophage by cycloastragenol contributes to amelioration of imiquimod-induced
- 467 *psoriasis-like skin inflammation in mice.* International Immunopharmacology, 2019. 74:
  468 p. 105682.
- 469 28. Chiang, C.-C., et al., *Neutrophils in psoriasis.* Frontiers in immunology, 2019. 10: p.
  470 2376.
- 471 29. Ding, Y., et al., *Mesenchymal stem/stromal cells primed by inflammatory cytokines*472 *alleviate psoriasis-like inflammation via the TSG-6-neutrophil axis.* Cell Death &
- 473 Disease, 2022. **13**(11): p. 996.
- 474 30. Xie, X., et al., *Single-cell transcriptome profiling reveals neutrophil heterogeneity in*475 *homeostasis and infection.* Nature immunology, 2020. 21(9): p. 1119-1133.
- 476 31. Stackowicz, J., et al., *Neutrophil-specific gain-of-function mutations in Nlrp3 promote*477 *development of cryopyrin-associated periodic syndrome.* Journal of Experimental
- 478 Medicine, 2021. **218**(10): p. e20201466.

- 479 32. Abram, C.L., et al., *Distinct roles for neutrophils and dendritic cells in inflammation and*
- 480 *autoimmunity in motheaten mice.* Immunity, 2013. **38**(3): p. 489-501.
- 481 33. Zheng, X., et al., *The role and mechanism of pyroptosis and potential therapeutic*
- 482 *targets in sepsis: a review.* Frontiers in immunology, 2021. **12**: p. 711939.
- 483 34. Aglietti, R.A. and E.C. Dueber, *Recent insights into the molecular mechanisms*
- 484 *underlying pyroptosis and gasdermin family functions.* Trends in immunology, 2017.
- 485 **38**(4): p. 261-271.
- 486 35. Shi, J., et al., *Cleavage of GSDMD by inflammatory caspases determines pyroptotic*
- 487 *cell death.* Nature, 2015. **526**(7575): p. 660-665.
- Wu, J., et al., *Treatment of severe acute pancreatitis and related lung injury by targeting gasdermin D-mediated pyroptosis.* Frontiers in cell and developmental
  biology, 2021. 9: p. 780142.
- 491 37. Shi, H., et al., *GSDMD-mediated cardiomyocyte pyroptosis promotes myocardial I/R*
- 492 *injury.* Circulation research, 2021. **129**(3): p. 383-396.
- 493 38. Al Mamun, A., et al., *Role of pyroptosis in spinal cord injury and its therapeutic*494 *implications.* Journal of Advanced Research, 2021. 28: p. 97-109.
- 49539.Verma, D., et al., Enhanced inflammasome activity in patients with psoriasis promotes
- 496 *systemic inflammation.* Journal of Investigative Dermatology, 2021. **141**(3): p. 586-595.
- 497 e5.
- 498 40. Zhang, C., et al., *Analysis of the potential pyroptosis mechanism in psoriasis and*499 *experimental validation of NLRP3 in vitro and in vivo.* International
  500 Immunopharmacology, 2023. **124**: p. 110811.

- 501 41. Wang, W.-M. and H.-Z. Jin, *Role of neutrophils in psoriasis.* Journal of Immunology
  502 Research, 2020. 2020.
- 503 42. Cai, Y., et al., A critical role of the IL-1 $\beta$ -IL-1R signaling pathway in skin inflammation
- 504 and psoriasis pathogenesis. Journal of investigative Dermatology, 2019. **139**(1): p.
- 505 146-156.
- 506 43. Dąbrowska, D., et al., *Many ways–one destination: different types of neutrophils death.*507 International Reviews of Immunology, 2019. **38**(1): p. 18-32.
- 508 44. Mrowietz, U., et al., *Clinical use of dimethyl fumarate in moderate-to-severe plaque-*
- 509 *type psoriasis: a European expert consensus.* Journal of the European Academy of
- 510 Dermatology and Venereology, 2018. **32**: p. 3-14.
- 511 45. Mrowietz, U. and K. Asadullah, *Dimethylfumarate for psoriasis: more than a dietary*
- 512 *curiosity.* Trends in molecular medicine, 2005. **11**(1): p. 43-48.
- 513 46. Humphries, F., et al., Succination inactivates gasdermin D and blocks pyroptosis.
- 514 Science, 2020. **369**(6511): p. 1633-1637.

515

517	Figure legends:
518	Figure1. The GSDMD-mediated pyroptosis is activated in psoriasis.
519	a) Expression of GSDMD in patients with psoriasis patients and healthy people from GSE178197,
520	GSE161683 and GSE153007.
521	b) Representative immunohistochemical staining of GSDMD in sections of skin tissue from
522	healthy individuals and patients with psoriasis. Scale bar = $100 \mu m$ .
523	c) Schematic representation of the IMQ-induced psoriasis mouse model.
524	d) Representative images and statistical analysis of western blot analysis showing the expression
525	of GSDMD and its N-terminal fragments in dorsal skin of WT mice treated with vehicle or
526	IMQ at day 4.
527	e) Representative images and statistical analysis of western blot analysis showing the expression
528	level of pro-caspase1 and caspase1 in dorsal skin of WT mice treated with vehicle or IMQ at day
529	4.
530	psn, psoriasis non-lesional skin; ps, psoriasis skin; con, control; HD, healthy donor; PP, pustular
531	psoriasis; IMQ, imiquimod; WT, wild-type. Error bars show mean ± SEM. *P < 0.05, **P < 0.01,
532	*** $P < 0.001$ , *** $P \le 0.0001$ . Data are representative of three independent experiments for (b, d,
533	e).
534	
535	Figure2. GSDMD deficiency mitigates psoriasis-like inflammation in mice.
536	a) Macroscopic phenotypic representation of the dorsal skin in WT and GSDMD-KO mice treated
537	with IMQ at day 4.
538	<b>b</b> ) Disease severity of psoriasis induced by IMQ in mice as assessed by PASI score (n=10-12).
539	c) Representative images and statistical analysis of hematoxylin and eosin staining of the dorsal
540	skin in WT and GSDMD-KO mice treated with IMQ at day 4 (n=5). Scale bar = $100 \mu m$ .
541	d) Representative images and statistical analysis of western blot analysis showing the expression
542	level of GSDMD and caspase1 in dorsal skin of WT and GSDMD-KO mice treated with IMQ at
543	day 4 (n=4).
544	e) Quantitative PCR analysis of the relative mRNA expression of proinflammatory cytokines in
545	the dorsal skin of WT and GSDMD-KO mice treated with IMQ at day 4 ( $n = 4$ ). Data were
546	normalized to a reference gene, Gapdh.
547	f) ELISA analysis of IL-6 and IL-1 $\beta$ per 1 mg of the dorsal skin from WT and GSDMD-KO mice
548	treated with IMQ at day 4 (n=5).
549	IMQ, imiquimod; WT, wild-type; KO, knockout; PASI, psoriasis Area and Severity Index. Error
550	bars show mean $\pm$ SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Data are representative of three
551	independent experiments for (a, c, d).
552	
553	
554	Figure3. Neutrophils undergo GSDMD mediated pyroptosis in psoriasis.
555	a) Expression of GSDMD in neutrophils in psoriasis patients and healthy people from
556	GSE123785.
557	b) Representative immunohistochemical staining of CD66b and GSDMD in two consecutive
558	sections of skin tissue from patients with psoriasis vulgaris or generalized pustular psoriasis. Scale
559	bar =100μm.
560	c) Dot plot of Gsdmd expression in each cell type in the skin of IMQ-induced psoriasis-like

561 mice (GSE165021).

d) Representative immunofluorescence of GSDMD (red), Ly6G (green) and nuclear (blue) in
dorsal skin of WT mice treated with vehicle, WT mice treated with IMQ and GSDMD-KO mice
treated with IMQ at day 5. Scale bar =50μm.

**e**) Representative and statistical graphs of the mean fluorescence intensity of propidium iodide inneutrophils from skin of WT mice as detected by flow cytometry(n=3).

567 ps, psoriasis skin; con, control; PV, psoriasis vulgaris; GPP, generalized pustular psoriasis; IMQ, 568 imiquimod; WT, wild-type; MFI, mean fluorescence intensity; PI, propidium iodide; MFO, 569 Fluorescence Minus One. Error bars show mean  $\pm$  SEM. \*P < 0.05. Data are representative of 570 three independent experiments for (b, d-e).

571

572

573 Figure4. GSDMD depletion in neutrophils attenuates the development of skin inflammation in574 psoriasis.

a) Representative images of western blot showing the expression of GSDMD in bonemarrow-derived neutrophils of cKO and isotype control mice.

b) Macroscopic phenotypic representation of the dorsal skin in control and GSDMD-cKO micetreated with IMQ at day 4.

**579 c**) Disease severity of psoriasis induced by IMQ in mice as assessed by PASI score (n=7).

d) Representative images and statistical analysis of hematoxylin and eosin staining of the dorsal
skin in control and GSDMD-cKO mice treated with IMQ at day 4 (n=5). Scale bar =100µm.

**e)** Quantitative PCR analysis of the relative mRNA expression of proinflammatory cytokines in
the dorsal skin of control and GSDMD-cKO mice treated with IMQ at day 4 (n = 4). Data were
normalized to a reference gene, Gapdh.

585 f) ELISA analysis of IL-6 and IL-1β per 1 mg of the dorsal skin from control and GSDMD-cKO
586 mice treated with IMQ at day 4(n=5).

**587 g)** Representative images and statistical analysis of western blot analysis showing the expression **588** level of GSDMD and its N-terminal fragments in dorsal skin of WT, cKO and  $Gsdmd^{-/-}$  mice **589** treated with IMQ at day 4 (n=4).

590 h) Schematic representation of the use of anti-Ly6G antibody in the IMQ-induced psoriasis mouse591 model.

592 i) Macroscopic phenotypic representation and PASI score of cKO mice and control mice treated593 with IMQ and Ly6G antibody.

594

595 cKO, conditional knockout. Error bars show mean ± SEM. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.</li>
596 Data are representative of three independent experiments for (a, b, d, g, i).

597

598

599 Figure S1

a) Expression level of *Ly6g* in each cell type in the skin of IMQ-induced psoriasis-like mice(GSE165021).

b) Representative immunofluorescence of TUNEL (red), Ly6G (green) and nuclear (blue) in

dorsal skin of WT mice treated with IMQ and GSDMD-KO mice treated with IMQ at day 4. Scale

 $bar = 50 \mu m$ . Statistical analysis of ratio of TUNEL positive cells in neutrophils. (n=7)

c) Expression level of *S100a8* in each cell type in the skin of IMQ-induced psoriasis-like
 mice (GSE165021).


607 Error bars show mean  $\pm$  SEM. ns, P $\ge$ 0.05. Data are representative of three independent


608 experiments for (b).


- 609
- 610 Figure S2
- **a**) Flow cytometry plots of neutrophil, isolated from dorsal skin of WT mice treated with IMQ.
- b) Uniform Manifold Approximation and Projection (UMAP) of single cells isolated from the
- 613 skin of IMQ-induced psoriasis-like mice (GSE165021), and feature plots showing
- 614 expression of *Il17a*, *Il6*, *Tnfa*, *Il1b* and *Il18*.
- 615 Data are representative of three independent experiments for (a).


616


# Figure.1











GSDMD

INO

e Vaseline IMQ **Full length** -45 -20 p20 **β**-actin -42 Caspase 1




Figure.2

